Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Baron

Showing results (151-160 of 198) with videos related to

Pageof 20
Sort By:
Journal of Personalized Medicine|December 24, 2025
Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) AxisAlireza Sharafshah, Kenneth Blum, Kai-Uwe Lewandrowski, et al.
Journal of Personalized Medicine|September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control SubjectsKenneth Blum, David Han, Ashim Gupta, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity IndexKenneth Blum, David Han, Abdalla Bowirrat, et al.
Journal of Personalized Medicine|December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent OpioidsMauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
American Journal of Lifestyle Medicine|January 12, 2026
Lifestyle Interventions for Major Depressive Disorder (MDD): An Expert Consensus Statement From the American College of Lifestyle MedicineGia Merlo, Steve Sugden, Richard M Rosenfeld, et al.
Frontiers in Bioscience (Elite Edition)|September 21, 2017
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependenceKenneth Blum, Amanda L C Chen, Panayotis K Thanos, et al.
Journal of the Neurological Sciences|September 9, 2022
Why haven't we solved the addiction crisis?Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
International Journal of Genomics and Data Mining|September 11, 2018
The Benefits of Genetic Addiction Risk Score (GARSKenneth Blum, Edward J Modestino, Marjorie Gondre-Lewis, et al.
Journal of Personalized Medicine|February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
EC Psychology and Psychiatry|June 26, 2023
Futuristic Thinking about Engineering "Geneospirituality" to Help Prevent Relapse of Reward Deficiency Syndrome (RDS) BehaviorsKenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
Pageof 20

Showing results (151-160 of 198) with videos related to

Sort By:
Pageof 20
Journal of Personalized Medicine|December 24, 2025
Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) AxisAlireza Sharafshah, Kenneth Blum, Kai-Uwe Lewandrowski, et al.
Journal of Personalized Medicine|September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control SubjectsKenneth Blum, David Han, Ashim Gupta, et al.
Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity IndexKenneth Blum, David Han, Abdalla Bowirrat, et al.
Journal of Personalized Medicine|December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent OpioidsMauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
American Journal of Lifestyle Medicine|January 12, 2026
Lifestyle Interventions for Major Depressive Disorder (MDD): An Expert Consensus Statement From the American College of Lifestyle MedicineGia Merlo, Steve Sugden, Richard M Rosenfeld, et al.
Frontiers in Bioscience (Elite Edition)|September 21, 2017
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependenceKenneth Blum, Amanda L C Chen, Panayotis K Thanos, et al.
Journal of the Neurological Sciences|September 9, 2022
Why haven't we solved the addiction crisis?Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
International Journal of Genomics and Data Mining|September 11, 2018
The Benefits of Genetic Addiction Risk Score (GARSKenneth Blum, Edward J Modestino, Marjorie Gondre-Lewis, et al.
Journal of Personalized Medicine|February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
EC Psychology and Psychiatry|June 26, 2023
Futuristic Thinking about Engineering "Geneospirituality" to Help Prevent Relapse of Reward Deficiency Syndrome (RDS) BehaviorsKenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
Pageof 20